Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 26

1.

Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation.

Nordell AD, McKenna M, Borges ÁH, Duprez D, Neuhaus J, Neaton JD; INSIGHT SMART, ESPRIT Study Groups; SILCAAT Scientific Committee.

J Am Heart Assoc. 2014 May 28;3(3):e000844. doi: 10.1161/JAHA.114.000844.

2.

Factors associated with D-dimer levels in HIV-infected individuals.

Borges AH, O'Connor JL, Phillips AN, Baker JV, Vjecha MJ, Losso MH, Klinker H, Lopardo G, Williams I, Lundgren JD; INSIGHT SMART Study Group; ESPRIT Study Group; SILCAAT Scientific Committee.

PLoS One. 2014 Mar 13;9(3):e90978. doi: 10.1371/journal.pone.0090978. eCollection 2014.

3.

Biomarkers and bacterial pneumonia risk in patients with treated HIV infection: a case-control study.

Bjerk SM, Baker JV, Emery S, Neuhaus J, Angus B, Gordin FM, Pett SL, Stephan C, Kunisaki KM; INSIGHT SMART Study Group.

PLoS One. 2013;8(2):e56249. doi: 10.1371/journal.pone.0056249. Epub 2013 Feb 15.

4.

Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection.

Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, Skoutelis A, Goetz MB, Phillips AN; INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study Group.

J Infect Dis. 2009 Sep 15;200(6):973-83. doi: 10.1086/605447.

5.

Interruption of antiretroviral therapy is associated with increased plasma cystatin C.

Mocroft A, Wyatt C, Szczech L, Neuhaus J, El-Sadr W, Tracy R, Kuller L, Shlipak M, Angus B, Klinker H, Ross M; INSIGHT SMART Study Group.

AIDS. 2009 Jan 2;23(1):71-82. doi: 10.1097/QAD.0b013e32831cc129.

6.

Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen.

Fox Z, Phillips A, Cohen C, Neuhaus J, Baxter J, Emery S, Hirschel B, Hullsiek KH, Stephan C, Lundgren J; SMART Study Group.

AIDS. 2008 Nov 12;22(17):2279-89. doi: 10.1097/QAD.0b013e328311d16f.

7.

Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial.

SMART Study Group, El-Sadr WM, Grund B, Neuhaus J, Babiker A, Cohen CJ, Darbyshire J, Emery S, Lundgren JD, Phillips A, Neaton JD.

Ann Intern Med. 2008 Sep 2;149(5):289-99.

PMID:
18765698
8.

Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up.

Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Lundgren JD, Babiker A, El-Sadr W, Emery S, Grund B, Neaton JD, Neuhaus J, Phillips AN.

J Infect Dis. 2008 Apr 15;197(8):1145-55. doi: 10.1086/529523.

PMID:
18476293
9.

Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.

Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, Gatell JM, Girard PM, Grund B, Law M, Losso MH, Palfreeman A, Wood R.

J Infect Dis. 2008 Apr 15;197(8):1133-44. doi: 10.1086/586713.

PMID:
18476292
10.

Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial.

DeJesus E, McCarty D, Farthing CF, Shortino DD, Grinsztejn B, Thomas DA, Schrader SR, Castillo SA, Sension MG, Gough K, Madison SJ; EPV20001 International Study Team.

Clin Infect Dis. 2004 Aug 1;39(3):411-8. Epub 2004 Jul 15.

PMID:
15307010
11.

Impact of an educational program on efficacy and adherence with a twice-daily lamivudine/zidovudine/abacavir regimen in underrepresented HIV-infected patients.

Rawlings MK, Thompson MA, Farthing CF, Brown LS, Racine J, Scott RC, Crawford KH, Goodwin SD, Tolson JM, Williams VC, Shaefer MS; NZTA4006 Helping to Enhance Adherence to Antiretroviral Therapy (HEART) Study Team.

J Acquir Immune Defic Syndr. 2003 Oct 1;34(2):174-83.

PMID:
14526206
12.

Pilot study of directly observed therapy in highly nonadherent HIV-infected patients in an urban community-based institution.

Khanlou H, Kandula VR, Yeh V, Stein TG, Sanchez S, Ricaurte JC, Bhatti L, Farthing CF.

J Acquir Immune Defic Syndr. 2003 Aug 15;33(5):651-3. No abstract available. Erratum in: J Acquir Immune Defic Syndr. 2003 Dec 15;34(5):536. Ricuarte, Juan Carlos [corrected to Ricaurte, Juan Carlos].

PMID:
12902813
13.

Evaluation of a hydrogen peroxide disinfectant for dental unit waterlines.

Linger JB, Molinari JA, Forbes WC, Farthing CF, Winget WJ.

J Am Dent Assoc. 2001 Sep;132(9):1287-91.

PMID:
11665356
14.

A necessary risk: why we doctors should volunteer to try an AIDS vaccine.

Farthing CF.

Washington Post. 1997 Oct 19:C1, C6. No abstract available.

PMID:
11647305
15.

Many patients suffer from 'battle fatigue': survey.

Farthing CF.

AIDS Alert. 2001 Jun;16(6):73-7, 70.

PMID:
11569967
16.

Increased CD4+ T-lymphocyte senescence fraction in advanced human immunodeficiency virus type 1 infection.

Nichols WS, Schneider S, Chan RC, Farthing CF, Daar ES.

Scand J Immunol. 1999 Mar;49(3):302-6.

17.

SIV vaccine for AIDS.

Farthing CF, Sullivan JL.

Science. 1998 Jan 2;279(5347):14-5. No abstract available.

PMID:
9441400
18.

Phosphonoformate (foscarnet): a pilot study in AIDS and AIDS related complex.

Farthing CF, Dalgleish AG, Clark A, McClure M, Chanas A, Gazzard BG.

AIDS. 1987 May;1(1):21-5.

PMID:
2962589
19.

Papillitis and hepatitis B.

Farthing CF, Howard RS, Thin RN.

Br Med J (Clin Res Ed). 1986 Jun 28;292(6537):1712. No abstract available.

20.

Clinical investigations of lymphadenopathy, including lymph node biopsies, in 24 homosexual men with antibodies to the human T-cell lymphotropic virus type III (HTLV-III).

Farthing CF, Henry K, Shanson DC, Taube M, Lawrence AG, Harcourt-Webster JN, Gazzard B.

Br J Surg. 1986 Mar;73(3):180-2.

PMID:
3004630

Supplemental Content

Loading ...
Support Center